HEMOPHILIA GENE THERAPY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Hemophilia Gene Therapy Market Size and Trends: 2026-2033

Hemophilia gene therapy market is estimated to be valued at USD 1,408 Mn in 2026 and is expected to reach USD 17,684 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 43.6% from 2026 to 2033.

Key Takeaways

• Based on Hemophilia Type, the Hemophilia A segment is expected to lead the market with 82% share in 2026, due to higher prevalence and greater clinical adoption.
• Based on Region, North America is set to lead the hemophilia gene therapy market with 43% share in 2026. While, Asia Pacific is anticipated to be the fastest growing region.

Market Overview
Increase in the incidence rate of hemophilia patients across the globe and the emphasis on long-term solutions are contributing to the growth of the hemophilia gene therapy market. The gene therapies provide an opportunity for a one-time cure that results in significant reduction in the incidence of bleeding episodes. This is resulting in increased demand from patients and providers. Increased advancements in virus vector systems and trials are contributing to the growth of the market. Increase in investments by biotechnology companies and positive government initiatives for the treatment of rare diseases are contributing to the growth of the market.

Current Events and Its Impacts on the Hemophilia Gene Therapy Market

How is product innovation driving the growth in hemophilia gene therapy?

• Next-Generation Viral Vectors: The creation of new, more secure and efficient vectors to improve gene delivery systems and mitigate associated immune issues.
• Personalized Gene Therapies: Developing treatments based on genetic characteristics to ensure higher response and lower toxicity.
• Combination Therapies: Gene therapy combined with other biological therapies or replacement therapies for optimal long-term results.
• Non-Viral Delivery Systems: New non-viral technologies such as lipid nanoparticles and mRNA technology are reducing risks for patients while also making them eligible for such treatments.

Segmental Insights

Hemophilia Gene Therapy Market Insights, By Hemophilia Type – Hemophilia A leads due to higher prevalence and clinical adoption

In terms of hemophilia type, the Hemophilia A segment is expected to constitute 82% of the market share by 2026, due to a higher prevalence compared to Hemophilia B and higher adoption of gene therapy treatments. Hemophilia A patients are the biggest target population for new therapies, and this has seen their R&D concentrated and with faster regulatory approvals.

For instance, in June 2025, BioMarin Pharmaceutical announced long-term results from its Phase 3 GENEr8 1 trial that found its gene therapy ROCTAVIAN (valoctocogene Roxaparvovec rVOX) continued to result in sustained factor VIII expression and bleed control five years after treating patients.

Regional Insights

North America Hemophilia Gene Therapy Market Analysis & Trends

North America is expected to dominate the hemophilia gene therapy market in 2026, with an estimated market share of 43%. The region’s market growth can be attributed to factors such as advanced healthcare infrastructure, early adoption of innovative gene therapies, strong presence of key pharmaceutical and biotech companies, and supportive regulatory and reimbursement frameworks.

For instance, in March 2025, the U.S. Food and Drug Administration (FDA) approved Qfitlia, a new bi‑monthly subcutaneous hemophilia therapy developed by Sanofi, for patients aged 12 and older with hemophilia A or B, with or without inhibitors.

Asia Pacific Hemophilia Gene Therapy Market Analysis & Trends

Asia Pacific region is expected to witness the highest growth rate in the year 2026, with factors attributing to its growth rate being increased healthcare spending, rising awareness among patients, increase in biotechnology investments, and the incidence rate of hemophilia. Countries such as China, Japan, and India are witnessing increased government initiatives and collaborations with private organizations to conduct clinical trials.

For instance, in April 2025, the National Medical Products Administration (NMPA) of China officially approved BBM‑H901 (Dalnacogene Ponparvovec Injection) for adults with moderate to severe hemophilia B.

Hemophilia Gene Therapy Market Outlook for Key Countries

Is the U.S. Hemophilia gene therapy market expanding due to approvals, partnerships, and adoption of advanced therapies?

The U.S. hemophilia gene therapy market is growing rapidly due to an increase in regulatory approvals, patient awareness, and high rate of adoption of latest treatments. The market is dominated by the U.S. followed by other countries due to high infatuation with infrastructure and reimbursement policies.

For instance, in March 2025, the U.S. FDA approved Qfitlia, a new subcutaneous therapy from Sanofi for hemophilia A and B patients aged 12 and above, offering more convenient dosing alongside existing gene therapies.

Is Japan’s focus on clinical research and partnerships driving market growth?

Japan’s hemophilia gene therapy market is witnessing growth due to robust clinical research, public-private collaborations, and increasing awareness among patients and healthcare providers. Initiatives to develop next-generation gene therapies are also expanding the pipeline.

For instance, in October 2025, Teijin Limited partnered with Cell Therapies Pty Ltd. (Australia) to expand cell and gene therapy infrastructure in Asia Pacific, including Japan.

Market Report Scope

Hemophilia Gene Therapy Market Driver

Increasing prevalence of hemophilia and unmet medical needs

The growing incidence of hemophilia, and particularly Hemophilia A, together with the limitations of currently available therapies, creates a strong and growing market for gene therapies, which provide lifelong solutions for patients, stopping bleeding and improving the quality of life. With the growing patient population, combined with a growing acceptance of advanced therapies by healthcare practitioners, the market is growing exponentially.

Hemophilia Gene Therapy Market Opportunity

Innovation in next-generation gene therapies and expansion into emerging regions

The market provides opportunities through the development of next-generation gene therapies that offer improved safety, efficacy, and delivery vehicles. The market also offers opportunities to increase penetration in growing emerging markets such as Asia Pacific and Latin America, where improved infrastructure and growing patient awareness offer a promise for future growth. Opportunities can be created through collaborations between biotechnology companies, academia, and government agencies to speed up product launches and advance clinical trials.

Analyst Opinion (Expert Opinion)

• The hemophilia gene therapy market is at a transformative stage, driven by innovations that are changing treatment from chronic management to potentially long-lasting solutions. Clinical outcomes from therapies such as ROCTAVIAN and Hemgenix demonstrate sustained factor expression and reduced bleeding episodes over multiple years, which is reshaping physician confidence and treatment protocols. These outcomes have encouraged specialists to increasingly consider gene therapy as a preferred option for eligible patients, reflecting a fundamental shift in clinical practice.
• North America continues to be the most developed market due to its sophisticated healthcare system, well-established regulatory framework, and high levels of patient and physician awareness. At the same time, Asia Pacific is quickly becoming a major growth region, with regulatory bodies expediting approvals and local biotech companies creating domestic gene therapies. Accessibility and adoption will be enhanced by the expansion of manufacturing and clinical trial capabilities brought about by strategic collaborations and partnerships in the region.

Top Strategies Followed by Hemophilia Gene Therapy Market Players

• Established biopharmaceutical companies focus on innovation and clinical excellence. Leading companies like BioMarin, CSL Behring, and Sanofi invest heavily in R&D to develop next-generation gene therapies with improved efficacy, safety, and delivery systems. These companies conduct extensive clinical trials, optimize viral vector designs, and expand manufacturing capacities to ensure consistent quality and scalability.
• Mid-sized biotech firms compete on the basis of strategic partnerships and clinical programs, where they may partner with academic groups, contract development organizations, or local biopharma companies to move forward their development pipelines, speed up regulatory filings, and shorten time-to-market for specific patient needs.
• Small-scale and niche biotech startups focus on unmet medical needs and novel platforms. These firms may explore innovative gene-editing technologies, rare mutation targeting, or patient-specific therapies. Collaborations with hospitals and research centers allow them to gain clinical credibility, while digital tools and patient registries help improve recruitment and trial efficiency.

Emerging Startups in the Hemophilia Gene Therapy Market

• Technological innovation is a key differentiator. Startups are exploring novel gene delivery methods, including CRISPR-based editing and next-generation AAV vectors, to enhance safety and therapeutic durability. If successful, these could redefine treatment paradigms and expand patient eligibility.
• Expanding access in emerging regions. Some startups focus on Asia Pacific and Latin America, developing cost-effective therapies and working with local regulatory authorities to increase patient access. Strategic collaborations with regional biotech firms help navigate market entry challenges.
• Specialized patient-focused solutions. Certain startups target underserved segments, such as patients with inhibitors or rare hemophilia mutations. By addressing these gaps, they build clinical differentiation and establish early adoption among specialist physicians.

Hemophilia Gene Therapy Industry News

• In December 2024, Spark Therapeutics announced the termination of its Phase 3 dirloctocogene samoparvovec gene therapy study for hemophilia while introducing a new enhanced‑function factor VIII variant and planning a future Phase 2b study.
• In February 2025, Pfizer announced it will halt global development and commercialization of its hemophilia B gene therapy Beqvez (fidanacogene elaparvovec‑dzkt) due to limited patient and physician uptake, effectively exiting the viral gene therapy space despite earlier regulatory approval.
• In April 2025, Belief BioMed and Takeda China jointly announced that BBM‑H901 (Dalnacogene Ponparvovec Injection), a gene therapy for adults with moderate to severe hemophilia B, was officially approved by China’s National Medical Products Administration (NMPA), marking the first locally developed hemophilia B gene therapy in China.

Market Segmentation

• Hemophilia Type Insights (Revenue, USD Mn, 2026 - 2033)
  • Hemophilia A
  • Hemophilia B
• Regional Insights (Revenue, USD Mn, 2026 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • BioMarin Pharmaceuticals, Inc.
  • Spark Therapeutics
  • Pfizer, Inc.
  • UniQure NV
  • Ultragenyx Pharmaceutical
  • Shire
  • Sangamo Therapeutics Inc.
  • Freeline Therapeutics

Sources

Primary Research Interviews

• Hemophilia Specialists & Hematologists
• Clinical Researchers in Gene Therapy
• Biopharmaceutical Company R&D Heads
• Regulatory Affairs & Market Access Professionals
• Hospital & Treatment Center Managers
• Patient Advocacy Group Representatives
• Others

Databases

• ClinicalTrials.gov
• PubMed
• FDA Database & Regulatory Filings
• European Medicines Agency (EMA) Database
• WHO Global Health Observatory
• NIH National Library of Medicine
• Others

Magazines

• BioPharma Dive
• Genetic Engineering & Biotechnology News (GEN)
• Pharmaceutical Technology
• Fierce Biotech
• BioWorld
• Others

Journals

• Blood (American Society of Hematology)
• Haemophilia (Journal of the World Federation of Hemophilia)
• Molecular Therapy (Nature Publishing Group)
• Gene Therapy (Nature Partner Journals)
• The New England Journal of Medicine
• Others

Newspapers

• The Wall Street Journal – Health & Pharma Section
• Financial Times – Life Sciences
• Reuters Health & Pharma News
• Bloomberg News – Biotech & Healthcare
• The New York Times – Health Section
• Others

Associations

• World Federation of Hemophilia (WFH)
• National Hemophilia Foundation (NHF)
• European Haemophilia Consortium (EHC)
• International Society on Thrombosis and Haemostasis (ISTH)
• Others

Public Domain Sources

• U.S. FDA – Hemophilia Gene Therapy Approvals & Guidelines
• EMA – European Regulatory Reports & Approvals
• ClinicalTrials.gov – Ongoing & Completed Trials
• WHO – Rare Diseases & Gene Therapy Publications
• PubMed & NIH Public Health Literature
• Others

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of Information for the Last 8 Years